References
- Consensus Development Meeting. Aspects of oral contraceptives of relevance for cardiovascular diseases. Am. J. Obstet. Gynecol. 1990; 162: 1335–7
- World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575–82
- World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low-oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582–8
- Jick H., Jick S. S., Gurewich V., Myers M. W., Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93
- Bloemenkamp K. W. M., Rosendaal F. R., Helmerhorst F. M., Buller H. R., Vanden-broucke J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593–6
- Spitzer W. O., Lewis M. A., Heinemann L. A., Thorogood M., MacRae K. D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br. Med. J. 1996; 312: 83–8
- Olsen C. M. Consensus Statements. Applying structure. J. Am. Med. Assoc 1995; 273: 72–3